Literature DB >> 31828584

A Novel Expression Profile of Cell Cycle and DNA Repair Proteins in Nonfunctioning Pituitary Adenomas.

Derya Metin-Armagan1, Nil Comunoglu2, Gulay Bulut3, Pinar Kadioglu4, Hiraku Kameda5, Nurperi Gazioglu6, Necmettin Tanriover7, Melek Ozturk8.   

Abstract

The molecular mechanisms underlying the formation of nonfunctioning pituitary adenomas (NFAs) are largely unknown. In this study, we aimed to understand the relationship between NFAs and functional pituitary adenomas and the possible role of proteins involved in cell cycle, senescence, and DNA damage control mechanisms in the etiology of NFA. We analyzed pATM-S1981, pRb-S608, Rb, pE2F1-S364, p16, E2F1, p73, cyclin D1, and CHEK2 protein expression (in a group of 20 patients with acromegaly, 18 patients with Cushing's disease (CD), and 29 NFA patients) by immunohistochemistry and their relevant mRNA expression by qRT-PCR (in a group of 7 patients with acromegaly, 7 patients with CD, and 7 NFA patients). The clinical and histopathological results on the patients were statistically evaluated. pE2F1-S364 protein expression in the CD group was significantly lower than that in the NFA and acromegaly groups (p = 0.025, p = 0.034, respectively). However, the expression of the p16 protein was lower than in the NFA group than in the CD and acromegaly groups (p = 0.030, p = 0.033, respectively), and E2F1 protein expression was significantly higher in the NFA group than in the CD group (p = 0.025). p73 protein expression in patients with acromegaly was significantly higher (p = 0.031) than that in the CD group. CHEK2 mRNA expression in the CD group was significantly higher than that in the acromegaly group (p = 0.012). The selective and tumor-specific associations between E2F1, pE2F1-S364, CHEK2, and p73 mRNA and protein levels indicate their involvement in pituitary adenoma formation in NFA, CD, and acromegaly patients.

Entities:  

Keywords:  CHEK2; E2F1; Nonfunctioning pituitary adenomas; RB; p16; p73; pE2F1-S364

Year:  2020        PMID: 31828584     DOI: 10.1007/s12022-019-09598-x

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  23 in total

Review 1.  Conserved functions of the pRB and E2F families.

Authors:  Sander van den Heuvel; Nicholas J Dyson
Journal:  Nat Rev Mol Cell Biol       Date:  2008-09       Impact factor: 94.444

2.  Results of immunohistochemical staining of cell-cycle regulators: the prediction of recurrence of functioning pituitary adenoma.

Authors:  Eun Hee Lee; Kyu Hong Kim; Jae Hyun Kwon; Hyung Dong Kim; Young Zoon Kim
Journal:  World Neurosurg       Date:  2013-09-22       Impact factor: 2.104

3.  TAp73 inhibits cell invasion and migration by directly activating KAI1 expression in colorectal carcinoma.

Authors:  Woo-Kyun Bae; Chang-Soo Hong; Mi-Ra Park; Eun-Gene Sun; Ji-Hee Lee; Keunsoo Kang; Kyung-Hyun Ryu; Hyun-Jeong Shim; Jun-Eul Hwang; Sang-Hee Cho; Ik-Joo Chung
Journal:  Cancer Lett       Date:  2017-12-06       Impact factor: 8.679

4.  Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses.

Authors:  Carlos S Moreno; Chheng-Orn Evans; Xianquan Zhan; Mammerhi Okor; Dominic M Desiderio; Nelson M Oyesiku
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

5.  Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island.

Authors:  D J Simpson; N A Hibberts; A M McNicol; R N Clayton; W E Farrell
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

6.  E2F1-mediated human POMC expression in ectopic Cushing's syndrome.

Authors:  Takako Araki; Ning-Ai Liu; Yukiko Tone; Daniel Cuevas-Ramos; Roy Heltsley; Masahide Tone; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2016-10-07       Impact factor: 5.678

Review 7.  Classification of pituitary adenomas.

Authors:  K Kovacs; E Horvath; S Vidal
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

8.  The effects of alpha lipoic acid on liver cells damages and apoptosis induced by polyunsaturated fatty acids.

Authors:  Fatma Kaya-Dagistanli; Gamze Tanriverdi; Ayfer Altinok; Sibel Ozyazgan; Melek Ozturk
Journal:  Food Chem Toxicol       Date:  2012-11-29       Impact factor: 6.023

9.  Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues.

Authors:  Hande Mefkure Ozkaya; Nil Comunoglu; Muge Sayitoglu; Fatma Ela Keskin; Sinem Firtina; Khusan Khodzhaev; Tugce Apaydin; Nurperi Gazioglu; Necmettin Tanriover; Buge Oz; Pinar Kadioglu
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

10.  E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression.

Authors:  Monica Fedele; Giovanna Maria Pierantoni; Rosa Visone; Alfredo Fusco
Journal:  Cell Div       Date:  2006-08-17       Impact factor: 5.130

View more
  4 in total

Review 1.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

2.  Increased E2F1 mRNA and miR-17-5p Expression Is Correlated to Invasiveness and Proliferation of Pituitary Neuroendocrine Tumours.

Authors:  Araceli García-Martínez; Beatriz López-Muñoz; Carmen Fajardo; Rosa Cámara; Cristina Lamas; Sandra Silva-Ortega; Ignacio Aranda; Antonio Picó
Journal:  Diagnostics (Basel)       Date:  2020-04-16

Review 3.  An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

Authors:  Shenzhong Jiang; Xiaokun Chen; Yinzi Wu; Renzhi Wang; Xinjie Bao
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

4.  Recurrent Acromegaly in a Patient With a CHEK2 Mutation.

Authors:  Milica Perosevic; Maria Martinez-Lage; Brooke Swearingen; Nicholas A Tritos
Journal:  AACE Clin Case Rep       Date:  2021-11-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.